Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft Versus Tumor Effects

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

Bone Marrow Transplantation volume 34, pages 511–514 (2004)Cite this article

Summary:

Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, prior salvage chemotherapy was administered. The median CD3+ cell dose administered was 77.5 × 106/kg (range 5–285). GVHD developed in all but one patient. The response rate was 4/9 (44%). Three of these four responders developed GVHD and 3/4 had received chemotherapy. No correlation was observed between CD3+ cell dose infused and disease response. At the latest follow-up, three patients are alive and six have expired (PD n=3, nonrelapse mortality n=3). The median response duration was 7 months (range 4–9), with one response currently ongoing. These data suggest that DLIs for immunotherapy of recurrent HL have significant activity, although they frequently leads to GVHD. The small sample size does not allow any conclusion as to whether chemotherapy administration increases the chance of response. The CD3 cell dose infused does not seem to correlate with disease response.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  2. Baron F, Beguin Y . Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 2000; 40: 468–476.

    Article  CAS  PubMed  Google Scholar 

  3. Porter DL, Collins RH, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214–1221.

    CAS  PubMed  Google Scholar 

  4. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318.

    CAS  PubMed  Google Scholar 

  5. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    CAS  PubMed  Google Scholar 

  6. Peggs KP, Thomson K, Chopra R et al. Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: evidence of a therapeutically relevant graft-versus-lymphoma effect. Blood 2003; 102: 198a (abstr.).

    Google Scholar 

  7. Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with hematologic malignancies. J Clin Oncol 2002; 20: 4022–4031.

    Article  PubMed  Google Scholar 

  8. Porter DL, Luger SM, Duffy KM et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Bl Marrow Transplant 2001; 7: 230–238.

    Article  CAS  Google Scholar 

  9. Anderlini P, Giralt S, Andersson B et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26: 615–620.

    Article  CAS  PubMed  Google Scholar 

  10. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572–578.

    Article  CAS  PubMed  Google Scholar 

  11. Milpied N, Fielding AK, Pearce R, et al., for the European group for blood and marrow transplantation. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996; 14: 1291–1296.

    Article  CAS  PubMed  Google Scholar 

  12. Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993; 11: 2342–2350.

    Article  CAS  PubMed  Google Scholar 

  13. Robinson SP, Sureda A, Mackinnon S et al. Reduced intensity allogeneic stem cell transplantation for Hodgkin's disease: an analysis from the European Group for Blood and Marrow Transplantation. Blood 2002; 100: 144a (abstr.).

    Article  Google Scholar 

  14. Akpek G, Ambinder RF, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314–4321.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are indebted to Muriel Giese for her secretarial assistance and Rima Saliba for her contribution to data analysis. We are also indebted to the staff nurses who provided outstanding care to these patients.

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    P Anderlini, S A Acholonu, G-J Okoroji, B S Andersson, D R Couriel, M J De Lima, M L Donato, I F Khouri, S A Giralt, N T Ueno & R E Champlin

Authors
  1. P Anderlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S A Acholonu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G-J Okoroji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B S Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D R Couriel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M J De Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M L Donato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I F Khouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N T Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Anderlini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderlini, P., Acholonu, S., Okoroji, GJ. et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 34, 511–514 (2004). https://doi.org/10.1038/sj.bmt.1704621

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704621

Keywords

This article is cited by

Search

Advanced search

Quick links